Catalyst Biosciences Past Earnings Performance
Past criteria checks 0/6
Catalyst Biosciences has been growing earnings at an average annual rate of 6.2%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been declining at an average rate of 5.7% per year.
Key information
6.2%
Earnings growth rate
28.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -5.7% |
| Return on equity | -1,257.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Catalyst Biosciences declares special one-time dividend of $1.43
Aug 25Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Aug 15Catalyst Biosciences plans to distribute $65M cash to stockholders
Jun 29Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11
Circling Back On Catalyst Biosciences
Dec 08Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Catalyst Biosciences EPS misses by $0.12, beats on revenue
May 06Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Catalyst Biosciences announces closing of $50M capital raise
Jan 29Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients
Dec 02What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow
Nov 18Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
Nov 14Revenue & Expenses BreakdownBeta
How Catalyst Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -44 | 13 | 0 |
| 30 Jun 23 | 0 | -48 | 15 | 0 |
| 31 Mar 23 | 0 | 7 | 16 | 0 |
| 31 Dec 22 | 1 | -8 | 17 | 0 |
| 30 Sep 22 | 3 | 12 | 17 | 0 |
| 30 Jun 22 | 6 | -8 | 17 | 0 |
| 31 Mar 22 | 7 | -80 | 18 | 0 |
| 31 Dec 21 | 7 | -88 | 19 | 0 |
| 30 Sep 21 | 7 | -87 | 19 | 0 |
| 30 Jun 21 | 6 | -77 | 18 | 0 |
| 31 Mar 21 | 6 | -75 | 18 | 0 |
| 31 Dec 20 | 21 | -56 | 16 | 0 |
| 30 Sep 20 | 19 | -51 | 15 | 0 |
| 30 Jun 20 | 18 | -48 | 15 | 0 |
| 31 Mar 20 | 16 | -44 | 13 | 0 |
| 31 Dec 19 | 0 | -55 | 13 | 0 |
| 30 Sep 19 | 0 | -52 | 14 | 0 |
| 30 Jun 19 | 0 | -47 | 13 | 0 |
| 31 Mar 19 | 0 | -40 | 13 | 0 |
| 31 Dec 18 | 0 | -30 | 12 | 0 |
| 30 Sep 18 | 0 | -25 | 11 | 0 |
| 30 Jun 18 | 1 | -23 | 11 | 0 |
| 31 Mar 18 | 1 | -26 | 11 | 0 |
| 31 Dec 17 | 1 | -26 | 10 | 0 |
| 30 Sep 17 | 1 | -24 | 10 | 0 |
| 30 Jun 17 | 1 | -22 | 10 | 0 |
| 31 Mar 17 | 1 | -17 | 9 | 0 |
| 31 Dec 16 | 0 | -17 | 9 | 0 |
| 30 Sep 16 | 0 | -18 | 10 | 0 |
| 30 Jun 16 | 0 | -19 | 10 | 0 |
| 31 Mar 16 | 1 | -15 | 10 | 0 |
| 31 Dec 15 | 2 | -15 | 10 | 0 |
| 30 Sep 15 | 2 | -11 | 8 | 0 |
| 30 Jun 15 | 3 | -7 | 6 | 0 |
| 31 Mar 15 | 2 | -8 | 5 | 0 |
| 31 Dec 14 | 2 | -7 | 4 | 0 |
| 31 Dec 13 | 1 | -10 | 4 | 0 |
Quality Earnings: CBIO is currently unprofitable.
Growing Profit Margin: CBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare CBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: CBIO has a negative Return on Equity (-1257.95%), as it is currently unprofitable.